Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

University of Nottingham

Headquarters: Nottingham, United Kingdom
Year Founded: 1881
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Jan 28, 2025
Emerging Company Profile

Isomab: Rebalancing VEGF-A isoforms to promote blood vessel formation

University of Nottingham spinout is developing an antibody for peripheral artery disease that turns VEGF’s cancer paradigm on its head
BioCentury | Nov 16, 2024
Management Tracks

Charlton becomes CSO of OMass

Plus: Zheng joins HBM and Nobias names Dougherty CEO
BioCentury | Sep 30, 2023
Discovery & Translation

DIOSynVax-Ethris sarbecovirus vaccine; plus CYR61 in NASH and more

BioCentury’s roundup of translational innovations
BioCentury | Feb 2, 2023
Emerging Company Profile

PrecisionLife: learning from genetic interactions by cutting noise

U.K. company untangling genomic interactions to find targets in complex diseases
BioCentury | May 24, 2022
Distillery Therapeutics

MvfR antagonist for biofilm-associated bacterial infections

BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Jun 26, 2020
Distillery Therapeutics

CDK12 identified as myotonic dystrophy target

BioCentury | Sep 27, 2019
Emerging Company Profile

Chain: engineering microbial delivery to the colon

Why Chain thinks its bacterial spore-based platform could help deliver therapies to the colon
Items per page:
1 - 10 of 46